14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
AH Diacon, R Dawson, F von Groote-Bidlingmaier… - The Lancet, 2012 - thelancet.com
Background New drugs, but also shorter, better-tolerated regimens are needed to tackle the
high global burden of tuberculosis complicated by drug resistance and retroviral disease …
high global burden of tuberculosis complicated by drug resistance and retroviral disease …
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary …
CD Tweed, R Dawson, DA Burger… - The Lancet …, 2019 - thelancet.com
Background New anti-tuberculosis regimens that are shorter, simpler, and less toxic than
those that are currently available are needed as part of the global effort to address the …
those that are currently available are needed as part of the global effort to address the …
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b …
R Dawson, AH Diacon, D Everitt, C van Niekerk… - The Lancet, 2015 - thelancet.com
Background New antituberculosis regimens are urgently needed to shorten tuberculosis
treatment. Following on from favourable assessment in a 2 week study, we investigated a …
treatment. Following on from favourable assessment in a 2 week study, we investigated a …
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South …
G Ferlazzo, E Mohr, C Laxmeshwar… - The Lancet Infectious …, 2018 - thelancet.com
Background Bedaquiline and delamanid have been approved for treatment of multidrug-
resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns …
resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns …
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and …
Background Globally rifampicin-resistant tuberculosis disease affects around 460,000
people each year. Currently recommended regimens are 9–24 months duration, have poor …
people each year. Currently recommended regimens are 9–24 months duration, have poor …
Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis
New regimens based on 2 or more novel agents are sought to shorten or to simplify
treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the …
treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the …
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial
KE Dooley, SL Rosenkranz, F Conradie… - The Lancet Infectious …, 2021 - thelancet.com
Background Bedaquiline and delamanid are the first drugs of new classes registered for
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in …
Background There is a need for short and safe all-oral treatment of rifampicin-resistant
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline
AH Diacon, R Dawson… - American journal of …, 2015 - atsjournals.org
Rationale: New regimens to shorten tuberculosis treatment and manage patients with drug-
resistant tuberculosis who are infected with HIV are urgently needed. Experimental and …
resistant tuberculosis who are infected with HIV are urgently needed. Experimental and …
Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary …
AH Diacon, R Dawson… - Antimicrobial agents …, 2013 - Am Soc Microbiol
Bedaquiline is a new antituberculosis agent targeting ATP synthase. This randomized,
double-blinded study enrolling 68 sputum smear-positive pulmonary tuberculosis patients …
double-blinded study enrolling 68 sputum smear-positive pulmonary tuberculosis patients …